Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; and Seroquel, Seroquel XR, Erzofri, Rivastigmine Multi-Day Transdermal Patch, and Rivastigmine. In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; and Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation. Further, it offers Oukai; Meibirui; Jinyouping; and other products. The company distributes and sells pharmaceutical drugs; research and development of antibody drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.